DexCom expects 2026 total revenue to be in a range of $5.16 billion to $5.25 billion, representing growth of 11% to 13% for the year. Sylvain indicated, "This guidance assumes continued strong ...

Feb 12 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab beat Wall Street estimates for fourth-quarter results on Thursday, driven by robust demand for its continuous glucose monitoring ...

Dexcom is already working on its G8 sensor for continuous glucose monitoring (CGM). But before you get too excited, the product is still a couple of years out, CEO Jake Leach told MD+DI during the J.P ...

Weeks after launching its first open call for diabetes advocates, Dexcom is spotlighting the resulting group of 16 people in a new awareness campaign. The project kicked off Friday, World Diabetes Day ...

Dexcom has been hit by a major safety issue for an Android version of its G6 continuous glucose monitoring system app, leading the FDA to issue its most serious recall notice. A “software defect in ...

Add Yahoo as a preferred source to see more of our stories on Google. Dexcom recalled an Android app for its G6 continuous glucose monitor because of a problem with the app stopping unexpectedly.

DexCom (DXCM) stock ought to be included on your watchlist. Here is why – it is presently trading within the support range ($55.31 – $61.13), levels from which it has bounced significantly in the past ...

Shares have lagged the market this year, partly due to some public image and regulatory issues. DexCom's stock could drop even more if results falls short of revenue expectations. Whatever happens on ...

Did a Netflix show wade too far into advertising in its second season? Many viewers found it distracting, even if some of it was organic. By Alisha Haridasani Gupta Midway through Season 2 of the ...

A recent investigation by Hunterbrook alleged that Dexcom "dropped the ball" in ensuring the accuracy and reliability of its G7 glucose monitoring device. Some patients reportedly experienced severe ...

San Diego-based Dexcom Inc., is the target of a class action lawsuit in U.S. district court over the company’s G7 continuous glucose monitors, an action which follows a U.S. FDA warning letter by a ...